Azithromycin anhydrous

This classification denotes a macrolide antibiotic with the molecular formula C38H72N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2KLZ20U1M, chemically known as 11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one but more generally known as azithromycin, which bears US NIH Compound Identifier 55185. Azithromycin most often comes in base and hydrate forms. European Medicines Agency schedules Azithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05660MIG. The term AZITHROMYCIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, No. 3, 1988, List 28). World Health Organization schedules azithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. AZITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule azithromycin anhydrous under HS 29419000. As of Q4 2014, AZITHROMYCIN ANHYDROUS remains US FDA's Preferred Term for this commodity. Azithromycin anhydrous bears US NLM identifiers UMLS ID C2698292 and NCI Concept Code C76213. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O.